Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Accounts Payables: 2016-2024

Historic Accounts Payables for UroGen Pharma (URGN) over the last 9 years, with Dec 2024 value amounting to $27.4 million.

  • UroGen Pharma's Accounts Payables rose 32.96% to $26.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.2 million, marking a year-over-year increase of 32.96%. This contributed to the annual value of $27.4 million for FY2024, which is 65.87% up from last year.
  • Per UroGen Pharma's latest filing, its Accounts Payables stood at $27.4 million for FY2024, which was up 65.87% from $16.5 million recorded in FY2023.
  • Over the past 5 years, UroGen Pharma's Accounts Payables peaked at $27.4 million during FY2024, and registered a low of $10.0 million during FY2020.
  • Its 3-year average for Accounts Payables is $18.8 million, with a median of $16.5 million in 2023.
  • Its Accounts Payables has fluctuated over the past 5 years, first dropped by 10.40% in 2020, then spiked by 65.87% in 2024.
  • Yearly analysis of 5 years shows UroGen Pharma's Accounts Payables stood at $10.0 million in 2020, then climbed by 20.74% to $12.1 million in 2021, then increased by 2.32% to $12.4 million in 2022, then surged by 33.55% to $16.5 million in 2023, then spiked by 65.87% to $27.4 million in 2024.